Nancy E. Kohl

12.4k total citations · 3 hit papers
97 papers, 8.0k citations indexed

About

Nancy E. Kohl is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Nancy E. Kohl has authored 97 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 36 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Nancy E. Kohl's work include Protein Kinase Regulation and GTPase Signaling (23 papers), Cancer-related Molecular Pathways (23 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Nancy E. Kohl is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (23 papers), Cancer-related Molecular Pathways (23 papers) and Cancer, Hypoxia, and Metabolism (11 papers). Nancy E. Kohl collaborates with scholars based in United States, Canada and Japan. Nancy E. Kohl's co-authors include Frederick W. Alt, W. Wayt Gibbs, Edward M. Scolnick, Allen Oliff, Lenora J. Davis, Richard A. Dixon, Connie E. Gee, Samuel Graham, S. J. DESOLMS and Irving S. Sigal and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Nancy E. Kohl

96 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Active human immunodeficiency virus protease is required for viral infectivity.

1988 1.1k citations Nancy E. Kohl, Emilio A. Emini et al. Proceedings of the National Academy of Sciences profile →
Transposition and amplification of oncogene-related sequences in human neuroblastomas

1983 607 citations Nancy E. Kohl, Naotoshi Kanda et al. profile →
Differential expression of myc family genes during murine development

1986 480 citations Nancy E. Kohl, Frederick W. Alt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy E. Kohl United States	42	5.2k	2.4k	1.1k	951	908	97	8.0k
Allen Oliff United States	43	4.1k 0.8×	2.6k 1.1×	157 0.1×	167 0.2×	371 0.4×	107	6.7k
Adrian M. Senderowicz United States	45	4.9k 0.9×	3.8k 1.6×	162 0.1×	254 0.3×	138 0.2×	110	8.1k
Lawrence R. Dick United States	35	6.0k 1.2×	2.1k 0.9×	136 0.1×	459 0.5×	119 0.1×	50	8.2k
Kristoffer Valerie United States	60	6.4k 1.2×	3.9k 1.6×	199 0.2×	223 0.2×	172 0.2×	164	10.4k
David F. Stern United States	64	7.6k 1.5×	5.8k 2.4×	428 0.4×	464 0.5×	57 0.1×	140	12.6k
Bradford Graves United States	26	5.2k 1.0×	3.6k 1.5×	110 0.1×	233 0.2×	207 0.2×	45	7.3k
P. Filippakopoulos United Kingdom	53	8.3k 1.6×	1.6k 0.7×	117 0.1×	242 0.3×	239 0.3×	87	9.8k
Thomas E. Smithgall United States	52	4.3k 0.8×	1.9k 0.8×	53 0.0×	819 0.9×	1.1k 1.3×	175	7.7k
Lyubomir T. Vassilev United States	36	7.0k 1.3×	5.0k 2.1×	170 0.2×	141 0.1×	117 0.1×	70	9.3k
Frank Podlaski United States	22	3.8k 0.7×	3.2k 1.3×	114 0.1×	226 0.2×	132 0.1×	26	7.2k

Countries citing papers authored by Nancy E. Kohl

Since Specialization

Citations

This map shows the geographic impact of Nancy E. Kohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy E. Kohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy E. Kohl more than expected).

Fields of papers citing papers by Nancy E. Kohl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy E. Kohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy E. Kohl. The network helps show where Nancy E. Kohl may publish in the future.

Co-authorship network of co-authors of Nancy E. Kohl

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy E. Kohl. A scholar is included among the top collaborators of Nancy E. Kohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy E. Kohl. Nancy E. Kohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagel, Margit, Chandra Miduturu, Michael P. Sheets, et al.. (2015). First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discovery. 5(4). 424–437. 247 indexed citations

Reardon, David A., Prafulla C. Gokhale, Sarah R. Klein, et al.. (2015). Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. 4(2). 124–135. 302 indexed citations

Cheng, Su–Chun, Ying Huang, Nancy E. Kohl, et al.. (2015). [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Translational Oncology. 8(3). 147–153. 4 indexed citations

Crompton, Brian D., Aaron R. Thorner, Amanda L. Christie, et al.. (2013). High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. Cancer Research. 73(9). 2873–2883. 42 indexed citations

Watters, James, Chun Cheng, Pradip K. Majumder, et al.. (2009). De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model. Cancer Research. 69(23). 8949–8957. 31 indexed citations

Rao, Sudhir, Jennifer O’Neil, James S. Hardwick, et al.. (2009). Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells. Cancer Research. 69(7). 3060–3068. 114 indexed citations

Ma, Yanhong, Shuxia Zhao, Joe Jiang Zhu, et al.. (2009). Real-time bioluminescence imaging of polycythemia vera development in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1792(11). 1073–1079. 2 indexed citations

Lutterbach, Bart, Qinwen Zeng, Lenora J. Davis, et al.. (2007). Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival. Cancer Research. 67(5). 2081–2088. 260 indexed citations

Ginanni, Nicole, Yanai Zhan, Michael R. Tota, et al.. (2007). Kinetic analysis of the fatty acid synthesis pathway in HCT-116 colon cancer cells: role of FAS and ACC1 in maintaining tumor cell viability and proliferation. Cancer Research. 67. 4473–4473. 2 indexed citations

10.

Hardwick, James S., Yi Yang, Chunsheng Zhang, et al.. (2005). Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Molecular Cancer Therapeutics. 4(3). 413–425. 24 indexed citations

11.

Fraley, Mark E., George D. Hartman, Carolyn A. Buser, et al.. (2005). Discovery of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Cancer Research. 65. 1463–1463. 1 indexed citations

12.

Bergman, Jeffrey M., Marc Abrams, Joseph P. Davide, et al.. (2001). Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry Letters. 11(11). 1411–1415. 25 indexed citations

13.

Nørgaard, Peter, Brian K. Law, Heather M. Joseph, et al.. (1999). Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.. PubMed. 5(1). 35–42. 55 indexed citations

14.

Taylor, Brigit R., et al.. (1999). In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood. 94(7). 2469–2476. 61 indexed citations

15.

Subler, Mark A., Elaine Rands, Charles A. Omer, et al.. (1998). A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis. Molecular and Cellular Biology. 18(1). 85–92. 147 indexed citations

16.

George, Rani E., A G McGuckin, Nancy E. Kohl, et al.. (1997). Analysis of candidate gene co-amplification with MYCN in neuroblastoma. European Journal of Cancer. 33(12). 2037–2042. 27 indexed citations

17.

Wai, John, Thorsten E. Fisher, Samuel Graham, et al.. (1994). Synthesis and biological activity of ras farnesyl protein transferase inhibitors. Tetrapeptide analogs with amino methyl and carbon linkages. Bioorganic & Medicinal Chemistry. 2(9). 939–947. 23 indexed citations

18.

Kohl, Nancy E., Scott D. Mosser, S. J. DESOLMS, et al.. (1993). Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor. Science. 260(5116). 1934–1937. 485 indexed citations

19.

Kohl, Nancy E., Emilio A. Emini, William A. Schleif, et al.. (1988). Active human immunodeficiency virus protease is required for viral infectivity.. Proceedings of the National Academy of Sciences. 85(13). 4686–4690. 1096 indexed citations breakdown →

20.

Shiloh, Yosef, Bruce R. Korf, Nancy E. Kohl, et al.. (1986). Amplification and rearrangement of DNA sequences from the chromosomal region 2p24 in human neuroblastomas.. PubMed. 46(10). 5297–301. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact